February 19, 2024

Recent and anticipated novel drug approvals for 2024

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing periodic updates on new and anticipated novel drug approvals.

Me gusta

Guardar

Cite This Study

Rim et al. (Mon,) studied this question.

synapsesocial.com/papers/68e78948b6db6435876fb47e https://doi.org/https://doi.org/10.1093/ajhp/zxae046

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER3012023 · 138 citations
2Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer2021 · 46 citations
3Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE),compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).2023 · 17 citations
4The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.2023 · 8 citations
5Recent and anticipated novel drug approvals for 2023 and 20242023 · 5 citations

Me gusta

Guardar